{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:12:13Z","timestamp":1788484333900,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jchromb.2026.125267","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:36:32Z","timestamp":1787787392000},"page":"125267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review"],"prefix":"10.1016","volume":"1283","author":[{"given":"V.","family":"Kavibharathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Thirusha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vijayadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.N.","family":"Nalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jchromb.2026.125267_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13679-023-00495-3","article-title":"Obesity stigma: causes, consequences, and potential solutions","volume":"12","author":"Westbury","year":"2023","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.jchromb.2026.125267_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100375","article-title":"Obesity: prevalence, causes, consequences, management, preventive strategies and future research directions","volume":"27","author":"Ahmed","year":"2025","journal-title":"Metabol Open."},{"issue":"7","key":"10.1016\/j.jchromb.2026.125267_bb0015","article-title":"The rising prevalence of obesity: part a: impact on public health","volume":"2","author":"Agha","year":"2017","journal-title":"Int J Surg Oncol (N Y)."},{"issue":"Suppl. 1","key":"10.1016\/j.jchromb.2026.125267_bb0020","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.2337\/dc26-S008","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association professional practice committee","year":"2026","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jchromb.2026.125267_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15010394","article-title":"Increasing obesity rates worldwide from 1976 to 2016: the obesity epidemic","volume":"15","author":"Keller","year":"2026","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.jchromb.2026.125267_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/cob.70072","article-title":"Burden of obesity in India: need for policy changes to attain highest possible level of health and well-being","volume":"16","author":"Kalra","year":"2026","journal-title":"Clin. Obes."},{"issue":"7","key":"10.1016\/j.jchromb.2026.125267_bb0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.jchromb.2026.125267_bb0040","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"18","author":"Alissou","year":"2026","journal-title":"J. Diabetes"},{"issue":"2","key":"10.1016\/j.jchromb.2026.125267_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70192","article-title":"Who wins the battle against obesity? A network meta-analysis comparing tirzepatide and semaglutide","volume":"18","author":"Bernardi","year":"2026","journal-title":"J. Diabetes"},{"issue":"5","key":"10.1016\/j.jchromb.2026.125267_bb0050","first-page":"434","article-title":"Method development and validation of semaglutide using RP-HPLC","volume":"6","author":"Varsha","year":"2021","journal-title":"Int. J. Pharm. Res. Appl."},{"issue":"1","key":"10.1016\/j.jchromb.2026.125267_bb0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cpan.2025.10.001","article-title":"Analytical advances in the quantitative and qualitative determination of clonidine and methyldopa: a review","volume":"22","author":"Mishra","year":"2026","journal-title":"Curr. Pharm. Anal."},{"issue":"2","key":"10.1016\/j.jchromb.2026.125267_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s40200-025-01711-8","article-title":"Semaglutide: properties, action and chromatographic analysis","volume":"24","author":"Wasilewska","year":"2025","journal-title":"J. Diabetes Metab. Disord."},{"key":"10.1016\/j.jchromb.2026.125267_bb0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.jchromb.2026.125267_bb0075","author":"Novo Nordisk"},{"key":"10.1016\/j.jchromb.2026.125267_bb0085","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9946924","article-title":"Glucagon-like peptide-1 receptor agonists for chronic weight management","volume":"2023","author":"Wojtara","year":"2023","journal-title":"Adv. Med."},{"issue":"1","key":"10.1016\/j.jchromb.2026.125267_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s13065-025-01716-7","article-title":"A multimodal HPLC stability-indicating approach for the estimation of semaglutide and tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal","volume":"20","author":"Khalil","year":"2026","journal-title":"BMC Chem."},{"issue":"10","key":"10.1016\/j.jchromb.2026.125267_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22159\/ijpps.2025v17i10.55557","article-title":"A review on HPLC method development and validation studies of combined dosage form of ivacaftor and tezacaftor","volume":"17","author":"Maddala","year":"2025","journal-title":"Int J Pharm Pharm Sci"},{"issue":"1","key":"10.1016\/j.jchromb.2026.125267_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2025.2483607","article-title":"The multifaceted effects of semaglutide: exploring its broad therapeutic applications","volume":"11","author":"Alkhatib","year":"2025","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.jchromb.2026.125267_bb0105","doi-asserted-by":"crossref","unstructured":"Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 Jan;109(1):6-16. doi: 10.1016\/j.kint.2025.10.005. Epub 2025 Nov 7. PMID: 41207620.","DOI":"10.1016\/j.kint.2025.10.005"},{"key":"10.1016\/j.jchromb.2026.125267_bb0110","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1111\/dom.70678","article-title":"Safety and pharmacokinetics of semaglutide 1.7 mg for obesity treatment in adolescents: a model-informed drug development approach","volume":"28","author":"Strathe","year":"2026","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.jchromb.2026.125267_bb0115","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/biomedicines11082127","article-title":"Metabolism and chemical degradation of new antidiabetic drugs: a review of analytical approaches for analysis of glutides and gliflozins","volume":"11","author":"Gumieniczek","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jchromb.2026.125267_bb0120","author":"Jones"},{"key":"10.1016\/j.jchromb.2026.125267_bb0125","series-title":"LC-MS Strategies for Analytical Characterization of GLP-1 Peptide Drugs [Internet]","author":"Sinha","year":"2026"},{"key":"10.1016\/j.jchromb.2026.125267_bb0130","author":"Maundrell"},{"issue":"7","key":"10.1016\/j.jchromb.2026.125267_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/sscp.70265","article-title":"Rise of peptide-based drugs: recent advancements in analytical strategies for peptide analysis","volume":"9","author":"Mannem","year":"2026","journal-title":"Sep. Sci. Plus"},{"key":"10.1016\/j.jchromb.2026.125267_bb0140","year":"2025","journal-title":"Anapharm"},{"issue":"2","key":"10.1016\/j.jchromb.2026.125267_bb0145","first-page":"35","article-title":"The benefits of combining UHPLC-UV and MS for peptide impurity profiling","volume":"32","author":"Samonig","year":"2019","journal-title":"BioPharm Int."},{"issue":"3","key":"10.1016\/j.jchromb.2026.125267_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70001","article-title":"Regulatory guidelines for the analysis of therapeutic peptides and proteins","volume":"31","author":"Elsayed","year":"2025","journal-title":"J Pept Sci"},{"issue":"2","key":"10.1016\/j.jchromb.2026.125267_bb0155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1091581820977846","article-title":"Development and regulatory challenges for peptide therapeutics","volume":"40","author":"Zane","year":"2021","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.jchromb.2026.125267_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105699","article-title":"Aspects of complexity in quality and safety assessment of peptide therapeutics and peptide-related impurities: a regulatory perspective","volume":"153","author":"Colalto","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"44","key":"10.1016\/j.jchromb.2026.125267_bb0165","doi-asserted-by":"crossref","first-page":"10122","DOI":"10.1039\/D0SM01011A","article-title":"A spectroscopic and molecular dynamics study on the aggregation process of a long-acting lipidated therapeutic peptide: the case of semaglutide","volume":"16","author":"Venanzi","year":"2020","journal-title":"Soft Matter"},{"issue":"18","key":"10.1016\/j.jchromb.2026.125267_bb0170","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/nano15181399","article-title":"Design of electrostatic nanocomplex of semaglutide with protamine and zinc for subcutaneous prolonged delivery","volume":"15","author":"Yang","year":"2025","journal-title":"Nanomaterials (Basel)."},{"issue":"4","key":"10.1016\/j.jchromb.2026.125267_bb0175","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1021\/acs.biomac.5c02669","article-title":"Fibrillar and micellar aggregation of semaglutide and formation of a chiral-imprinted glass","volume":"27","author":"Castelletto","year":"2026","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jchromb.2026.125267_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2024.111686","article-title":"Blueness, whiteness, and greenness appraisal of sensitive chromatographic approach for determination of semaglutide concurrently with pioglitazone and metformin using green mobile phase; alongside with pharmacokinetic study","volume":"207","author":"Mansour","year":"2024","journal-title":"Microchem. J."},{"issue":"8","key":"10.1016\/j.jchromb.2026.125267_bb0195","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1007\/s10895-024-03954-9","article-title":"RGB trichromatic whiteness assessment of bioanalytical chromatographic tool using fluorescence for quantitation of semaglutide: application to pharmaceutical preparations and spiked plasma","volume":"35","author":"Moneim","year":"2025","journal-title":"J. Fluoresc."},{"issue":"1","key":"10.1016\/j.jchromb.2026.125267_bb0200","first-page":"15","article-title":"Analytical method and validation for the estimation of antidiabetic agent semaglutide in bulk form and marketed pharmaceutical dosage form by RP-HPLC","volume":"9","author":"Sahoo","year":"2026","journal-title":"J Innov Dev Pharm Tech Sci."},{"key":"10.1016\/j.jchromb.2026.125267_bb0205","series-title":"TN-1386: optimized HPLC method for assay and separation of semaglutide from its known impurities\/related substances using Aeris peptide XB-C18 [internet]","author":"Arunkumar","year":"2023"},{"issue":"4","key":"10.1016\/j.jchromb.2026.125267_bb0210","first-page":"1046","article-title":"Development and validation of novel stability-indicating RP-HPLC method for determination of semaglutide in tablet dosage form","volume":"11","author":"Deshpande","year":"2023","journal-title":"Int J All Res Educ Sci Methods."},{"issue":"11","key":"10.1016\/j.jchromb.2026.125267_bb0215","first-page":"684","article-title":"A quantitative RP-HPLC approach for the method development and validation for the simultaneous quantification of semaglutide and liraglutide in pharmaceutical dosage forms","volume":"18","author":"Joshna Sree","year":"2022","journal-title":"J Xi\u2019an Shiyou Univ Nat Sci Ed."},{"issue":"3","key":"10.1016\/j.jchromb.2026.125267_bb0220","first-page":"36","article-title":"Development and validation of stability indicating assay method for estimation of semaglutide bulk and pharmaceutical dosage form by RP-HPLC","volume":"13","author":"Kumar","year":"2022","journal-title":"J Glob Trends Pharm Sci."},{"key":"10.1016\/j.jchromb.2026.125267_bb0225","series-title":"Optimized HPLC method for assay and separation of semaglutide from its known impurities\/related substances using Aeris\u2122 peptide XB-C18","author":"Arunkumar","year":"2025"},{"issue":"7","key":"10.1016\/j.jchromb.2026.125267_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics18070770","article-title":"Development and validation of a liquid chromatography\/tandem mass spectrometry method for the quantification of the GLP-1 analog semaglutide in rat plasma, and its application in a pharmacokinetic study","volume":"18","author":"Kim","year":"2026","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jchromb.2026.125267_bb0240","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ipha.2025.01.002","article-title":"Development and validation of a UPLC-HR-SIM method to quantify semaglutide for its pharmacokinetic study","volume":"3","author":"Jiang","year":"2025","journal-title":"Intelligent Pharmacy."},{"issue":"13","key":"10.1016\/j.jchromb.2026.125267_bb0245","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17576180.2025.2535954","article-title":"In-vitro metabolite identification for MEDI7219, an oral GLP-1 analog, using LC-MS\/MS with CID and EAD approaches","volume":"17","author":"Liu","year":"2025","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2026.125267_bb0250","series-title":"Low-ng\/mL quantitation of glucagon-like peptide-1 (GLP-1) analog in rat plasma [internet]","author":"Selen","year":"2023"},{"key":"10.1016\/j.jchromb.2026.125267_bb0255","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.2147\/JIR.S391859","article-title":"Effects of semaglutide on cardiac protein expression and cardiac function of obese mice","volume":"15","author":"Pan","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"4","key":"10.1016\/j.jchromb.2026.125267_bb0260","first-page":"295","article-title":"A validated method development for the estimation of semaglutide in its bulk and pharmaceutical dosage form by using UV-visible spectrophotometer","volume":"9","author":"Rajita","year":"2022","journal-title":"Eur. J. Pharm. Med. Res."},{"issue":"2","key":"10.1016\/j.jchromb.2026.125267_bb0265","first-page":"394","article-title":"Method development and validation of semaglutide by UV spectrophotometric method in bulk and pharmaceutical dosage form","volume":"6","author":"Penmetsa","year":"2019","journal-title":"International Journal of Research and Analytical Reviews."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226003569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226003569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:15:39Z","timestamp":1788480939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226003569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":48,"alternative-id":["S1570023226003569"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125267","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125267"}}